---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-258907"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2022-10-06T23:59:59+00:00"
generated_at: "2026-06-23T05:08:14.025128+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lyell Immunopharma receives FDA IND clearance for LYL845 TIL therapy for solid tumors

## Summary
- FDA cleared IND for LYL845, an autologous TIL therapy enhanced with Epi-R reprogramming technology.
- Phase 1 trial initially enrolling relapsed/refractory metastatic or locally advanced melanoma; expansion into NSCLC and colorectal cancer.
- Initial clinical data expected in 2024; patient screening to begin in coming months.
- LYL845 is Lyell's first TIL product candidate and second wholly owned IND clearance within the past year.

## SEC filing metadata
- accession: 0001193125-22-258907
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2022-10-06T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000119312522258907/0001193125-22-258907-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000119312522258907/d407382d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-258907
- JSON: https://secwatch.observer/filing/0001193125-22-258907.json
- Plain text: https://secwatch.observer/filing/0001193125-22-258907.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.